Literature DB >> 10812498

Features of polymyositis and dermatomyositis in the elderly: a case-control study.

E Pautas1, P Chérin, J C Piette, S Pelletier, B Wechsler, J Cabane, S Herson.   

Abstract

OBJECTIVE: Polymyositis (PM) and dermatomyositis (DM) are uncommon idiopathic inflammatory myopathies (IIM). Little is known about these diseases in the elderly. We attempted to define the characteristics of PM/DM in the elderly by a case-control study involving the retrospective review of medical files of PM/DM patients.
METHODS: We drew from among 200 PM/DM patients being followed in our Internal Medicine Department 21 patients (14 F/7 M), aged > or = 65 years at the onset of myositis (17 PM/4 DM) (mean: 69.9 +/- 4.8 yrs.). They were compared with 21 (15 F/6 M) randomly selected younger patients with IIM: PM (14) and DM (7) (mean: 46.4 +/- 12.4 yrs). Clinical, biological, electrophysiological and pathologic features, treatment regimens and side-effects in the 2 groups were collected.
RESULTS: Clinical features were similar for the 2 groups. Elderly patients tended to have a higher frequency of cancer (24% vs 9.5%, p = 0.06), particularly of rectal adenocarcinoma. The time from disease onset to diagnosis was significantly longer in older patients (26 +/- 37 months vs 9 +/- 15 months; p = 0.02), normal CK levels were more frequent (40% vs 5%; p = 0.02) and serum CK levels were lower than for the population as the whole (11.5 N vs 22 N, p < 0.03). Electromyography features were more frequently suggestive of a chronic form of the disease in elderly patients. Treatment regimens and short-term side-effects were similar for the 2 groups.
CONCLUSION: PM and DM are often diagnosed late in the elderly. Biological data and electromyography features argue for a chronic form of the disease in this age group. Clinical and endoscopic rectal examinations should be carried out in elderly patients with PM/DM.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10812498

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  8 in total

1.  When myopathy strikes in a cancer patient.

Authors:  Srivalli Gopaluni; Lilian M Thomas; Chirag Shah
Journal:  Gastrointest Cancer Res       Date:  2009-09

2.  Dermatomyositis: analysis of 109 patients surveyed at the Hospital das Clínicas (HCFMUSP), São Paulo, Brazil.

Authors:  Luciena Cegatto Martins Ortigosa; Vitor Manuel Silva dos Reis
Journal:  An Bras Dermatol       Date:  2014 Sep-Oct       Impact factor: 1.896

3.  Clinical, electrophysiologic, and histopathologic profile, and outcome in idiopathic inflammatory myositis: An analysis of 68 cases.

Authors:  K N Ramesha; Abraham Kuruvilla; P S Sarma; V V Radhakrishnan
Journal:  Ann Indian Acad Neurol       Date:  2010-10       Impact factor: 1.383

4.  Paraneoplastic dermatomyositis revealing undifferentiated nasopharyngeal carcinoma at early stage: a case report.

Authors:  Souleymane Panandtigri; Nioka Pierre Xavier Siaˡ; Meryeme Charkaouiˡ; Nadia Benchakrounˡ; Zineb Bouchbikaˡ; Hassan Jouhadiˡ; Nezha Tawfiqˡ; Souha Sahraouiˡ; Abdellatif Beniderˡ
Journal:  J Med Case Rep       Date:  2022-01-04

5.  Clinical characteristics and outcomes of juvenile and adult dermatomyositis.

Authors:  Sang-Jun Na; Seung Min Kim; Il Nam Sunwoo; Young-Chul Choi
Journal:  J Korean Med Sci       Date:  2009-07-30       Impact factor: 2.153

6.  [Dermatomyositis in the elderly: a study of 4 cases in southern Tunisia].

Authors:  Faten Frikha; Mouna Snoussi; Raida Ben Salah; Noura Saidi; Neila Kaddour; Zouhir Bahloul
Journal:  Pan Afr Med J       Date:  2012-10-06

Review 7.  Malignancy in patients with inflammatory myopathy.

Authors:  Rachelle Buchbinder; Catherine L Hill
Journal:  Curr Rheumatol Rep       Date:  2002-10       Impact factor: 4.686

8.  Malignancy in dermatomyositis and polymyositis: analysis of 192 patients.

Authors:  Yao-Fan Fang; Yeong-Jian Jan Wu; Chang-Fu Kuo; Shue-Fen Luo; Kuang-Hui Yu
Journal:  Clin Rheumatol       Date:  2016-05-23       Impact factor: 3.650

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.